Vaxcyte

Pneumococcal disease vaccine
#Clinical trial #FDA #Immunology / Virology & Vaccines #Pneumonia #Regulatory #United States #Vaxcyte

Breakthrough Therapy designation for pneumococcal disease vaccine

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.  The decision was based on positive topline results from a Phase I/II proof-of-concept study, which evaluated the safety, tolerability and immunogenicity of VAX-24 in… Read More

#News #Regulatory